Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.